LCN2 and cholestasis: Besides monitoring the pTEC injury marker KIM-1 which may be an early marker of CN in patients with cholestasis,7 monitoring serum and/or urinary NGAL is a promising strategy for detecting tubular damage (i.e. subclinical AKI) that preceded the functional impairment that defines AKI in the clinic.